Alnylam Gets EU Approval for AMVUTTRA in ATTR Amyloidosis
First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of Wild-Type or Hereditary ATTR Amyloidosis with Cardiomyopathy – Novel RNAi Mechanism...
Tag : cardiovascular
RyCarma Therapeutics Names Elizabeth Tarka, M.D., CMO
RyCarma Therapeutics, Inc., a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases, has appointed Elizabeth Tarka, M.D., as its...
Reflow Medical Expands Global Reach with New European Subsidiary
Reflow Medical, Inc., a leading developer of innovative medical devices for complex cardiovascular disease, has announced the opening of its European subsidiary in Landsberg am...